2024 年至 2031 年微流控市场（按产品、应用、最终用户和地区划分）

微流控市场评估 - 2024-2031

对即时诊断测试的需求不断增长，推动了微流体技术的采用。精准流体操作增强药物发现和市场开发过程将推动市场规模从 2024 年的 416.3 亿美元增至 2031 年的约 1,994.2 亿美元。

此外，个人化医疗的日益增长的需求也刺激了微流体技术的应用。微流体系统减少了实验室和临床环境中的试剂消耗和营运成本，推动市场在 2024 年至 2031 年期间以 23.86% 的复合年增长率成长。

微流体市场定义/概述

微流体技术是指在微米尺度上操纵和控制流体的科学和技术。该领域涉及能够处理微量液体（如微升和纳升）的设备的设计和製造。微流体系统利用通道、阀门和泵浦来精确管理流体流动，从而实现多个产业的广泛应用。

微流体技术最重要的应用之一是在生物医学领域，尤其是诊断和药物传输。微流体设备有助于快速有效地分析血液和唾液等生物样本，从而实现更早的疾病检测和个人化医疗。它们还用于将多种测试功能整合到单一晶片上的晶片实验室系统，大大提高了医疗测试的速度和准确性。

对即时诊断（POC）的需求不断增长将如何促进微流体技术的采用？

对即时诊断（POC）的需求不断增长是微流体市场发展的主要驱动力。微流体技术可实现快速、便携且经济高效的诊断解决方案，使其成为医疗保健环境中 POC 应用的理想选择。根据美国国立卫生研究院的数据，预计2022年全球POC诊断市场价值将达到293亿美元，预计将快速成长。这种成长是由对快速且准确的诊断工具的需求所推动的，特别是在资源有限的环境中。近日，雅培实验室宣布推出全新ID NOW™ COVID-19检测，该检测利用微流控技术，最快五分钟即可得出结果，展示了微流控在快速诊断方面的潜力。

製药业向个人化医疗的转变正在推动微流体市场的发展。微流体设备在药物发现、开发和测试中非常有用，因为它们可以精确控制少量流体。美国食品药物管理局（FDA）在2022年核准了34种个人化药物，占当年所有新药核准的34%。这项统计数据凸显了个人化医疗日益增长的重要性。顺应这一趋势，丹纳赫集团旗下的 Molecular Devices 公司最近推出了 QPix™ 微生物菌落筛选器，该设备采用微流体技术来增强药物研发过程。

器官晶片技术的进步正在推动微流体市场的发展。这些微流体装置模拟人体器官的生理条件，为传统细胞培养和动物测试提供了更精确的替代方法。美国国家转化科学促进中心报告称，自 2012 年以来，该中心已在组织晶片研究上投资超过 2 亿美元，凸显了这项技术的重要性。针对这一最新趋势，Emulate, Inc. 最近推出了 Brain Chip，这是一种模拟人类血脑屏障的微流体设备。

微流体终端用户产业的需求波动会抑制市场成长吗？

微流体市场面临着与设计和製造复杂设备相关的高昂开发成本的课题。创建精确的微流体系统通常需要先进的材料和製造技术，这可能会很昂贵。这些成本阻碍了小型企业和新创公司进入市场，从而减少了竞争和创新。

监管障碍也是一个重大障碍，尤其是在医疗和製药领域。用于诊断和药物输送的微流体设备必须符合卫生当局製定的严格法规和标准。冗长的审批流程会延迟产品的发布、增加製造商的成本，并且难以跟上快速的技术变更。

终端用户产业的需求波动也可能影响微流体市场的成长。研究资金、医疗保健需求和工业应用的波动可能导致对微流体产品的需求不一致。经济衰退和优先事项的转变将导致投资减少，从而进一步加剧该领域製造商和开发商的市场稳定。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况 市集亮点

第3章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

• 设备
• 元件晶片感测器
• 微针
• 泵
• 阀门

第 5 章微流体市场按应用划分

• 体外诊断
• 概念验证
• 临床
• 兽医
• 调查
• 蛋白质体学
• 基因组
• 基于单元格
• 毛细管
• 製造

第6章 微流体市场（依最终用户划分）

• 药品
• 医院

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第10章 公司简介

赛默飞世尔科技（美国）
• PerkinElmer Inc.（美国）
• Beckton Dickinson and Company（美国） 安捷伦科技公司（美国） Bio-Rad Laboratories, Inc.（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 丹纳赫集团（美国） Illumina 公司（美国） Fluidigm 公司（瑞士） 雅培实验室（美国） Dolomite Microfluidics（英国）
• 派克汉尼汾公司（美国）

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

Microfluidics Market Valuation - 2024-2031

Increasing demand for point-of-care testing is propelling the adoption of microfluidics. Enhanced drug discovery and development processes benefit from precise fluid manipulation is driving the market size surpass USD 41.63 Billion valued in 2024 to reach a valuation of around USD 199.42 Billion by 2031.

In addition to this, rising need for personalized medicine is spurring up the adoption of microfluidics. Microfluidic systems reduce reagent consumption and operational costs in laboratories and clinical settings, this is enabling the market grow at a CAGR of 23.86% from 2024 to 2031.

Microfluidics Market: Definition/ Overview

Microfluidics refers to the science and technology of manipulating and controlling fluids at the micrometer scale. This field involves the design and fabrication of devices that can handle very small volumes of liquids, often in the range of microliters or nanoliters. Microfluidic systems utilize channels, valves, and pumps to precisely manage fluid flow, enabling a wide range of applications across various industries.

One of the most significant applications of microfluidics is in the biomedical field, particularly for diagnostics and drug delivery. Microfluidic devices can facilitate rapid and efficient analysis of biological samples, such as blood or saliva, allowing for early disease detection and personalized medicine. Additionally, they are used in laboratory-on-a-chip systems that integrate multiple laboratory functions into a single chip, greatly enhancing the speed and accuracy of medical testing.

How Growing Demand for Point-Of-Care (POC) Diagnostics Increase Adoption of Microfluidics?

The growing demand for point-of-care (POC) diagnostics has been a significant driver of the Microfluidics Market. Microfluidic technologies enable rapid, portable, and cost-effective diagnostic solutions, making them ideal for POC applications in healthcare settings. According to the National Institutes of Health, the global POC diagnostics market was valued at $29.3 billion in 2022 and is expected to grow rapidly. This growth is fueled by the need for quick and accurate diagnostic tools, especially in resource-limited settings. Recently, Abbott Laboratories announced the launch of their new ID NOW(TM) COVID-19 test, which utilizes microfluidic technology to deliver results in as little as 5 minutes, demonstrating the potential of microfluidics in rapid diagnostics.

The pharmaceutical industry's shift towards personalized medicine has boosted the Microfluidics Market. Microfluidic devices enable precise control over small volumes of fluids, making them invaluable for drug discovery, development, and testing. The U.S. Food and Drug Administration (FDA) approved 34 personalized medicines in 2022, accounting for 34% of all new drug approvals that year. This statistic underscores the growing importance of tailored therapeutics. In line with this trend, Danaher Corporation's subsidiary, Molecular Devices, recently introduced the QPix(TM) Microbial Colony Picker, which incorporates microfluidic technology to enhance drug discovery processes.

Advancements in organ-on-a-chip technology have propelled the Microfluidics Market forward. These microfluidic devices mimic the physiological conditions of human organs, offering a more accurate alternative to traditional cell cultures and animal testing. The National Center for Advancing Translational Sciences reported that it has invested over USD 200 Million in tissue chip research since 2012, highlighting the significance of this technology. Responding to this growing field, Emulate, Inc. recently launched their Brain-Chip, a microfluidic device that models the human blood-brain barrier, potentially revolutionizing drug development for neurological disorders.

Will Fluctuating Demand from End-User Industries of Microfluidics Restraining the Market Growth?

The microfluidics market encounters challenges due to high development costs associated with designing and fabricating complex devices. Creating precise microfluidic systems often requires advanced materials and manufacturing techniques, which can be expensive. These costs can deter smaller companies and startups from entering the market, leading to reduced competition and innovation.

Regulatory hurdles also present a significant restraint, particularly in the medical and pharmaceutical sectors. Microfluidic devices used for diagnostics and drug delivery must comply with stringent regulations and standards set by health authorities. The lengthy approval processes can delay product launches and increase costs for manufacturers, making it difficult for them to keep pace with rapid technological advancements.

Also, fluctuating demand from end-user industries can impact the growth of the microfluidics market. Variations in research funding, healthcare needs, and industrial applications can lead to inconsistent demand for microfluidic products. Economic downturns or shifts in priorities can result in decreased investments, further complicating market stability for manufacturers and developers in this field.

Category-Wise Acumens

Which Factors are Contributing to Device Segment Dominance in Microfluidics Market?

The device segment has emerged as the dominant force in the microfluidics market, driven by the increasing adoption of point-of-care diagnostic devices and lab-on-a-chip systems. These microfluidic devices offer rapid, portable, and cost-effective solutions for various applications in healthcare, research, and environmental monitoring. According to the National Institutes of Health, the global market for microfluidic devices in healthcare was valued at $15.7 billion in 2022 and is projected to grow significantly. Recently, Danaher Corporation's subsidiary, Cepheid, announced the launch of their new GeneXpert Omni system, a portable molecular diagnostics platform utilizing microfluidic technology for rapid testing in remote settings.

In the pharmaceutical industry, microfluidic devices are revolutionizing drug discovery and development processes. These devices enable high-throughput screening, precise drug delivery, and personalized medicine applications. The U.S. Food and Drug Administration reported that in 2023, approximately 25% of all new drug approvals utilized microfluidic technologies in their development process. Addressing this trend, Thermo Fisher Scientific recently introduced their new Gibco CTS Rotea Counterflow Centrifugation System, which incorporates microfluidic technology for cell therapy manufacturing, demonstrating the growing importance of microfluidic devices in advanced therapeutic development.

Which Factors Enhance the Use of Microfluidics in In Vitro Diagnostics (IVD)?

The in vitro diagnostics (IVD) segment is a dominant force in the microfluidics market, driven by the increasing demand for rapid, accurate, and cost-effective diagnostic solutions. Microfluidic technologies enable the miniaturization and automation of complex diagnostic procedures, leading to improved efficiency and reduced sample volumes. According to the U.S. Food and Drug Administration, the number of approved IVD devices utilizing microfluidic technology increased by 35% between 2020 and 2023, highlighting the growing adoption of this technology in diagnostics. Recently, Roche Diagnostics announced the launch of their cobas(R) pure integrated solutions system, which incorporates microfluidic technology to provide high-speed, compact clinical chemistry and immunoassay testing.

The COVID-19 pandemic has significantly accelerated the growth of the IVD segment in the Microfluidics Market, with a particular focus on rapid point-of-care testing. Microfluidic-based diagnostic devices have played a crucial role in the global response to the pandemic by enabling quick and accurate detection of SARS-CoV-2. The World Health Organization reported that as of December 2023, over 60% of approved rapid COVID-19 tests utilized microfluidic technologies. In response to this demand, Abbott Laboratories expanded their ID NOW(TM) platform, introducing new tests for influenza A & B, strep A, and RSV, all leveraging microfluidic technology for rapid results at the point of care.

Country/Region-wise Acumens

Will Early Adoption of Technologies in North America Drive Microfluidics Market Growth?

The North American microfluidics market has been experiencing rapid growth in recent years, driven by advancements in healthcare technology and increasing demand for point-of-care diagnostics. According to the National Institutes of Health (NIH), as of 2022, the U.S. government has invested over USD 500 Million in microfluidics research and development over the past decade. This substantial funding has fueled innovation and accelerated the adoption of microfluidic technologies across various industries, including pharmaceuticals, biotechnology, and environmental monitoring.

The market's expansion is further propelled by the rising prevalence of chronic diseases and the need for more efficient and cost-effective diagnostic solutions. A report from the U.S. Food and Drug Administration (FDA) in 2023 revealed that microfluidic-based diagnostic devices have shown a 30% reduction in time-to-result compared to traditional methods. This improved efficiency has led to increased interest from both healthcare providers and patients, driving market growth. Additionally, the COVID-19 pandemic has heightened awareness of the importance of rapid, accurate diagnostic tools, further boosting the adoption of microfluidic technologies.

Will Burgeoning Pharmaceutical and Biotechnology Industries Enhance Adoption of Microfluidics in Asia Pacific?

The Asia-Pacific region is emerging as a dominant force in the microfluidics market, driven by rapid technological advancements, increasing healthcare expenditure, and growing research activities. Countries like China, Japan, and South Korea are at the forefront of microfluidics adoption in various applications, including diagnostics, drug discovery, and environmental monitoring. According to the World Health Organization, healthcare spending in the Asia-Pacific region increased by 6.3% annually between 2018 and 2022, outpacing global averages. Recently, Danaher Corporation announced the expansion of its microfluidics research and development center in Singapore, highlighting the region's growing importance in the global microfluidics landscape.

The burgeoning pharmaceutical and biotechnology industries in Asia-Pacific have significantly contributed to the region's dominance in the microfluidics market. Microfluidic technologies are increasingly being utilized in drug discovery processes and personalized medicine applications. The China National Medical Products Administration reported that the number of innovative drug approvals in China increased by 40% from 2020 to 2023, with a significant portion utilizing microfluidic technologies in their development. Addressing this trend, Thermo Fisher Scientific recently launched a new microfluidic-based single-cell sequencing platform in collaboration with Chinese researchers, aimed at accelerating genomic studies and drug discovery efforts in the region.

Competitive Landscape

The microfluidics market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the microfluidics market include:

• Abbott Laboratories
• Roche Diagnostics
• Illumina, Inc.
• Thermo Fisher Scientific
• Agilent Technologies
• PerkinElmer, Inc.
• Bio-Rad Laboratories
• Beckman Coulter, Inc.
• RainDance Technologies
• Fluidigm Corporation
• Elveflow
• Siemens Healthineers
• Micronit Microfluidics

10X Genomics

• uFluidics
• Dolomite Microfluidics
• Aline Biosciences
• Luminex Corporation
• Syrris Ltd.
• Celerion

Latest Developments

• In October 2023, a consortium of biotech companies announced a collaboration to enhance microfluidic chip technologies for rapid diagnostic applications, aiming to improve disease detection and patient outcomes.
• In September 2023, researchers at a leading university unveiled a breakthrough in microfluidic systems that allows for real-time monitoring of biochemical reactions, potentially revolutionizing laboratory processes.

Microfluidics Market, By Category

• Product:
• Device
• Component Chip Sensor
• Microneedle
• Pump
• Valve
• Application:
• IVD
• POC
• Clinical
• Vet
• Research
• Proteomic
• Genomic
• Cell-based
• Capillary
• Manufacturing
• End-User:
• Pharmaceutical
• Hospital
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Microfluidics Market, By Product

• Device
• Component Chip Sensor
• Microneedle
• Pump
• Valve

5. Microfluidics Market, By Application

• IVD
• POC
• Clinical
• Vet
• Research
• Proteomic
• Genomic
• Cell-based
• Capillary
• Manufacturing

6. Microfluidics Market, By End-User

• Pharmaceutical
• Hospital

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Thermo Fisher Scientific (US)
• PerkinElmer Inc. (US)
• Beckton Dickinson and Company (US)
• Agilent Technologies, Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• Illumina, Inc. (US)
• Fluidigm Corporation (Switzerland)
• Abbott Laboratories (US)
• Dolomite Microfluidics (UK)
• Parker Hannifin Corporation (US

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References